Business Context and Reporting Period
Company: OKYO Pharma Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 28, 2026
Context: The filing discloses an insider transaction involving the purchase of company shares by an executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific insider trading event rather than financial performance.
Material Changes and Insider Activity
- Insider Purchase: Raj Patil, PhD, Chief Scientific Officer, purchased 3,363 ordinary shares.
- Transaction Price: $1.49 per share.
- Exchange: NASDAQ.
- Post-Transaction Holdings: 20,030 ordinary shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document serves solely to report the share purchase and incorporates the news announcement as Exhibit 99.1.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the significance of the 3,363 share purchase.
- Confirm the current market price of OKYO Pharma shares relative to the $1.49 transaction price.
- Review the full text of Exhibit 99.1 for any additional context regarding the Chief Scientific Officer's confidence in the company.
- Check for any other recent insider transactions to identify broader trends in executive sentiment.